Suppr超能文献

自适应气溶胶输送(AAD)技术:过去、现在和未来。

The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.

机构信息

Philips Respironics, Respiratory Drug Delivery Ltd, Chichester, United Kingdom.

出版信息

J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S1-10. doi: 10.1089/jamp.2009.0791.

Abstract

Conventional aerosol delivery systems and the availability of new technologies have led to the development of "intelligent" nebulizers such as the I-neb Adaptive Aerosol Delivery (AAD) System. Based on the AAD technology, the I-neb AAD System has been designed to continuously adapt to changes in the patient's breathing pattern, and to pulse aerosol only during the inspiratory part of the breathing cycle. This eliminates waste of aerosol during exhalation, and creates a foundation for precise aerosol (dose) delivery. To facilitate the delivery of precise metered doses of aerosol to the patient, a unique metering chamber design has been developed. Through the vibrating mesh technology, the metering chamber design, and the AAD Disc function, the aerosol output rate and metered (delivered) dose can be tailored to the demands of the specific drug to be delivered. In the I-neb AAD System, aerosol delivery is guided through two algorithms, one for the Tidal Breathing Mode (TBM), and one for slow and deep inhalations, the Target Inhalation Mode (TIM). The aim of TIM is to reduce the treatment time by increasing the total inhalation time per minute, and to increase lung deposition by reducing impaction in the upper airways through slow and deep inhalations. A key feature of the AAD technology is the patient feedback mechanisms that are provided to guide the patient on delivery performance. These feedback signals, which include visual, audible, and tactile forms, are configured in a feedback cascade that leads to a high level of compliance with the use of the I-neb AAD System. The I-neb Insight and the Patient Logging System facilitate a further degree of sophistication to the feedback mechanisms, by providing information on long term adherence and compliance data. These can be assessed by patients and clinicians via a Web-based delivery of information in the form of customized graphical analyses.

摘要

传统的雾化输送系统和新技术的出现,推动了“智能”雾化器的发展,如 I-neb 适应性雾化输送(AAD)系统。基于 AAD 技术,I-neb AAD 系统被设计为能够持续适应患者呼吸模式的变化,并仅在呼吸周期的吸气部分输送雾化药物。这避免了雾化药物在呼气过程中的浪费,并为精确的雾化药物(剂量)输送奠定了基础。为了方便向患者输送精确计量的雾化药物,开发了一种独特的计量室设计。通过振动网技术、计量室设计和 AAD 盘功能,可以根据要输送的特定药物的需求,调整雾化药物输出率和计量(输送)剂量。在 I-neb AAD 系统中,雾化药物输送由两种算法控制,一种用于潮气量呼吸模式(TBM),另一种用于缓慢而深的吸气,即目标吸气模式(TIM)。TIM 的目的是通过增加每分钟的总吸气时间来缩短治疗时间,并通过缓慢而深的吸气减少在上呼吸道中的冲击,从而增加肺部沉积。AAD 技术的一个关键特点是提供了患者反馈机制,以指导患者进行输送操作。这些反馈信号包括视觉、听觉和触觉形式,以反馈级联的形式配置,以确保患者高度依从 I-neb AAD 系统的使用。I-neb Insight 和患者记录系统通过提供长期依从性和合规性数据,为反馈机制提供了进一步的精细化程度。患者和临床医生可以通过基于网络的信息传递,以定制的图形分析形式,评估这些数据。

相似文献

1
The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S1-10. doi: 10.1089/jamp.2009.0791.
2
Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S37-43. doi: 10.1089/jamp.2009.0786.
3
The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S55-9. doi: 10.1089/jamp.2009.0793.
4
Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S45-54. doi: 10.1089/jamp.2009.0777.
5
In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S11-20. doi: 10.1089/jamp.2009.0792.
6
Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S29-36. doi: 10.1089/jamp.2009.0768.
7
Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):iii-v. doi: 10.1089/jamp.2010.0818.
9
Adaptive Aerosol Delivery (AAD) technology.
Expert Opin Drug Deliv. 2004 Nov;1(1):165-76. doi: 10.1517/17425247.1.1.165.
10

引用本文的文献

1
Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.
Pharmaceutics. 2024 Jan 10;16(1):97. doi: 10.3390/pharmaceutics16010097.
2
Nebuliser systems for drug delivery in cystic fibrosis.
Cochrane Database Syst Rev. 2023 Nov 9;11(11):CD007639. doi: 10.1002/14651858.CD007639.pub3.
3
Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives.
Pharmaceutics. 2021 Sep 12;13(9):1455. doi: 10.3390/pharmaceutics13091455.
4
In vitro evaluation of disposable transport ventilators with combination aerosol therapy.
BMJ Open Respir Res. 2021 Mar;8(1). doi: 10.1136/bmjresp-2020-000739.
5
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.
Adv Drug Deliv Rev. 2021 Feb;169:100-117. doi: 10.1016/j.addr.2020.12.004. Epub 2020 Dec 9.
6
Future Trends in Nebulized Therapies for Pulmonary Disease.
J Pers Med. 2020 May 10;10(2):37. doi: 10.3390/jpm10020037.
7
Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.
J Aerosol Med Pulm Drug Deliv. 2019 Oct;32(5):317-339. doi: 10.1089/jamp.2018.1508. Epub 2019 Jul 9.
8
lloprost delivered via the BREELIB nebulizer: a review of the clinical evidence for efficacy and safety.
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619835497. doi: 10.1177/1753466619835497.
9
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.
Int J Mol Sci. 2017 May 16;18(5):1062. doi: 10.3390/ijms18051062.

本文引用的文献

1
Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S61-70. doi: 10.1089/jamp.2009.0767.
2
Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S45-54. doi: 10.1089/jamp.2009.0777.
3
Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S37-43. doi: 10.1089/jamp.2009.0786.
4
Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S29-36. doi: 10.1089/jamp.2009.0768.
5
The Adaptive Aerosol Delivery system in a telehealth setting: patient acceptance, performance and feasibility.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S21-7. doi: 10.1089/jamp.2009.0770.
6
In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S11-20. doi: 10.1089/jamp.2009.0792.
8
Adherence to nebulised antibiotics in cystic fibrosis.
Patient Educ Couns. 2009 Apr;75(1):141-4. doi: 10.1016/j.pec.2008.08.027. Epub 2008 Oct 25.
9
Aerosol delivery devices in the treatment of asthma.
Respir Care. 2008 Jun;53(6):699-723; discussion 723-5.
10
Adaptive Aerosol Delivery (AAD) technology.
Expert Opin Drug Deliv. 2004 Nov;1(1):165-76. doi: 10.1517/17425247.1.1.165.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验